SHINE3hOpinion
China biotech becomes powerful player in research for new drug therapies
A recent CNN report cast a spotlight on Akeso, a Chinese biotech company whose immunotherapy ivonescimab drug, now in ...
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...
Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1, a self-developed and ...
Pharmabiz2d
Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia
Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.
Akeso, Inc.: Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment ...
CNN5d
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine
In September, Akeso, a little-known Chinese biotech company founded nearly a decade ago shook up the biotech sector with its new lung cancer drug. Ivonescimab, the new drug, was found in a trial ...
Morningstar5d
Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in ...
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer ...